Boehringer Ingelheim Reports Additional Data from the P-II Study of Survodutide to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Shots:
- BI previously reported the P-II study data of survodutide vs PBO, showing improved MASH & a biopsy-proven improved MASH in ~83.0% vs 18.2% of patients post 48wks. without worsening fibrosis
- Now, the trial’s sub-analysis demonstrated 64.5% vs 25.9% of patients with fibrosis (F2 & F3) had improved fibrosis without worsening of MASH while 2EP depicted improved liver scarring stages (F1, F2, F3) in 52.3% vs 25.8% of them post 48wks. Data was highlighted at EASL 2024 and published in the NEJM
- Furthermore, ~87.0% of adults had at least a 30% vs 19.7% reduced liver fat, with liver fat content reductions of up to 64.3% vs 7.3% and a Non-alcoholic Fatty Liver Disease Activity Score (NAS) improvement of up to -3.3 vs -0.4
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
